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Abstract
Rationale: Epstein-Barr virus (EBV) is the causative pathogen for infectious mononucleosis and many
kinds of malignancies including several lymphomas such as Hodgkin's lymphoma, Burkitt's lymphoma and
NK/T cell lymphoma as well as carcinomas such as nasopharyngeal carcinoma (NPC) and EBV-associated
gastric carcinoma (EBV-GC). However, to date no available prophylactic vaccine was launched to the
market for clinical use.
Methods: To develop a novel vaccine candidate to prevent EBV infection and diseases, we designed
chimeric virus-like particles (VLPs) based on the hepatitis B core antigen (HBc149). Various VLPs were
engineered to present combinations of three peptides derived from the receptor binding domain of EBV
gp350. All the chimeric virus-like particles were injected into Balb/C mice for immunogenicity evaluation.
Neutralizing titer of mice sera were detected using an in vitro cell model.
Results: All chimeric HBc149 proteins self-assembled into VLPs with gp350 epitopes displayed on the
surface of spherical particles. Interestingly, the different orders of the three epitopes in the chimeric
proteins induced different immune responses in mice. Two constructs (149-3A and 149-3B) induced high
serum titer against the receptor-binding domain of gp350. Most importantly, these two VLPs elicited
neutralizing antibodies in immunized mice, which efficiently blocked EBV infection in cell culture.
Competition analysis showed that sera from these mice contained antibodies to a major neutralizing
epitope recognized by the strong neutralizing mAb 72A1.
Conclusion: Our data demonstrate that HBc149 chimeric VLPs provide a valuable platform to present
EBV gp350 antigens and offer a robust basis for the development of peptide-based candidate vaccines
against EBV.
Key words: Epstein-Barr virus, Envelope glycoprotein, gp350, Conserved epitope peptide, HBc149, Chimeric
virus-like particle, Neutralizing antibody.
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Introduction
Epstein-Barr virus (EBV), a widespread human
γ-herpesvirus, causes persistent infection in more
than 95% of the world population [1, 2]. Primary EBV
infection is usually asymptomatic and often occurs
during childhood. EBV is the major cause of infectious
mononucleosis (IM) and is also tightly linked to
various malignancies including Hodgkin's lymphoma
(HL), Burkitt's lymphoma (BL), NK/T cell lymphoma,
nasopharyngeal carcinoma (NPC) and gastric
carcinoma (GC) [3]. Immunocompromised individuals such as transplant recipients and AIDS patients
are at increased risk of developing EBV-associated
malignancies [4-7].
It is urgent to develop an effective vaccine to
prevent EBV infection [8, 9]. However, to date, there is
no approved vaccine against EBV infection and
EBV-associated diseases. EBV encodes many envelope
glycoproteins. The most abundant glycoprotein on the
virion surface, gp350 has been one of the most studied
targets for development of a prophylactic subunit
vaccine to neutralize infection of B cells. In response
to natural EBV infection, gp350 is the major
immunogen to induce a neutralizing antibody
response in human sera, which protects B cells against
infection [10, 11]. Immunization with antigens
comprising glycoproteins from the viral fusion
apparatus (gH/gL, gH/gL/gp42 and gB) have
elicited robust antibody response that have the
advantage of neutralizing infection of B cells as well
as epithelial cells [12-15] . Thus, the fusion apparatus
glycoproteins have become components of choice in
the design of prophylactic vaccines. Finally,
antibodies against EBV BMRF2 prevented virus
attachment and and entry into epithelial cells [16]. The
need for efficient protection of the two EBV target cell
types in vivo, B cells and epithelial cells, will likely
require immunization with combinations of viral
glycoprotein antigens using common platform such as
nanoparticles or VLPs. Recombinant gp350/220
proteins expressed in E.coli and insect cells were used
to define the region reacting with the virus capsid
antigen (VCA)-positive human sera [17]. MAbs
against gp350/220 showed neutralizing activity to
prevent EBV infection [18, 19]. A representative
mouse monoclonal antibody (mAb) 72A1, effectively
blocked EBV infection of B cells [20, 21]. Moreover,
mAb 72A1 directly bound to an epitope on the
glycan-free surface which was identified as the
receptor binding domain (RBD) of gp350 [22, 23]. The
interaction between gp350 and the complement
receptor type2 (CR2/CD21) on B lymphocytes is
needed to trigger infection. The RBD is located at the
N-terminus of gp350, and soluble proteins containing
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the RBD (i.e. gp350FL, gp3501-470) could block EBV
infection of B cells. Overall, these data show the
importance of the RBD of gp350 as a target for
neutralization and support the use of the gp350 RBD
as a promising subunit vaccine candidate against
EBV.
Several approaches have been tested to develop
an efficient vaccine candidate based on gp350 [9].
Soluble forms of the gp350 ectodomain expressed in
CHO cells exhibited native conformation, bound the
receptor CR2 and were recognized by several specific
mAbs. The monomeric form of gp350 with native
conformation induced high serum antibody titer that
effectively neutralized EBV in vitro [24]. A truncated
version of gp350 (gp3501-443), which contained the
RBD, was produced from Pichia pastoris and induced
high levels of specific antibodies and a strong T cell
response in mice [25]. In addition, multimerization of
gp350 antigens was shown to improve efficiency of
vaccine candidates. Cui et al. demonstrated that a
tetrameric gp3501-470 antigen induced higher
neutralizing titer [26]. Recently, we showed that the
dimeric antigen gp350ECD123 (amino acid 1-425,
referring to the first three N-terminal domains) fused
with immunoglobulin Fc fragments elicited a stronger
humoral immune response in mice compared to the
monomeric counterpart [27]. When expressed on
self-assembling nanoparticles based on the ferritin
protein, the gp350 RBD induced potent and durable
neutralizing antibodies that prevented EBV infection
in challenged mice [15]. VLPs based on Newcastle
disease virus (NDV) matrix and nucleocapsid were
engineered by fusing the gp350 ectodomain or RBD
with the NDV F protein. These NDV-VLPs bound to
CD21 and CD35 and elicited a long-lasting
neutralizing antibody response in mice [28]. A cell
line, HEK293-VII+, was engineered to produce
EBV-derived VLP lacking viral DNA but presenting
full-length gp350, gp140 and gp125 on their surface.
These VLPs induced strong humoral response in a
murine model in vivo and stimulated CD8+ and CD4+
T cell responses in vitro [29].
Furthermore, nonhuman primates immunized
with different gp350-based vaccine candidates were
protected from EBV-induced lymphomas when
challenged with native virus. Immunization with
purified membrane containing gp350 (previously
named gp340) or with recombinant gp350 could
protect tamarins from EBV-induced diseases [30-33].
Recombinant vaccinia virus and replication defective
adenovirus expressing gp340 effectively protected
cottontop tamarins from EBV-induced malignant
lymphomas [34-36].
Recently, gp350-based candidate vaccines have
been evaluated in human clinical trials. A vaccinia
http://www.thno.org
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virus vector-based vaccine was tested in infants and
all developed neutralizing antibodies [37]. In a phase I
and I/II clinical trial, a recombinant subunit
gp350-based
vaccine
elicited
gp350-specific
neutralizing antibodies [38]. In addition, recombinant
gp350 adjuvanted with aluminum hydroxide and
3-O-desacy-4’-monophosphory lipid A (AS04)
efficiently prevented IM but did not prevent EBV
acquisition in a cohort of seronegative individuals
[39]. A gp350-based vaccine was also tested in 13
children patients with chronic kidney disease.
Neutralizing antibodies were detected in four
recipients but the immune response declined rapidly
[40]. These attempts highlight the benefits of gp350
immunization but also the needs to improve
immunogenicity and promote a long lasting immune
response.
Epitope peptides are considered to be valuable
vaccine candidates, especially for conserved
neutralizing epitopes [41, 42]. Several peptides
derived from the gp350 RBD efficiently blocked CR2
binding to EBV or to recombinant gp350 and could
bind to CR2-positive B cells. Additionally, antibodies
directed against these peptides inhibited EBV binding
to B cells [43, 44].
Compared to full-length or truncated protein
antigens, linear peptides do not present conformationdependent epitopes. Although peptides allow
targeting of precise functional domain, their
conformational limitations may restrict the
immunogenicity of peptide-based vaccines. The
immunogenicity of epitope peptides with low
molecular
weights
can
be
enhanced
by
multimerization [16] or by presentation of the
peptides on the surface of recombinant VLPs. Here we
used chimeric VLPs formed by the C-terminally
truncated Hepatitis B virus core (HBc) protein (149
aa), which have been considered as an ideal delivery
vehicle for peptides derived from HIV, HCV, EV71,
CA16, VZV, HEV, ZIKV and dengue virus [45-51].
Practically, chimeric HBc proteins produced in E.coli
self-assemble and display foreign epitope peptides on
the surface of VLPs [52, 53]. The region between
amino acid 78 and 82 (MIR) is an ideal insertion site
because it is surface accessible and not required for
HBc self-assembly [54, 55]. In this study, we selected
three peptides named P1 (aa 16-29), P2 (aa 142-161)
and P3 (aa 282-301) from the gp350 RBD and used the
truncated HBc149 as an immune carrier. The three
peptides were inserted into the MIR of HBc149 in
different tandem order combinations. All five
constructs yielded well-formed spherical particles.
Interestingly, different arrangements of the three
epitopes greatly influenced the humoral response of
immunized mice. Two configurations, 149-3A
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(P1P2P3) and 149-3B (P1P3P2) elicited high antibody
titers against gp350ECD123 (corresponding to
gp3501-425), while other combinations were poorly
immunogenic. In addition, sera collected from 149-3A
and 149-3B immunized mice showed high
competitive activity with a neutralizing mAb 72A1,
thereby indicating the presence of Abs against a major
neutralizing epitope of gp350. More importantly, sera
from 149-3A and 149-3B-immunized mice neutralized
EBV infection of cells in vitro. Altogether these data
support the use of HBc-VLPs as useful vectors for
gp350 peptides to induce anti-EBV neutralizing
antibodies.

Materials and Methods
Plasmids Construction for Expression of
Recombinant HBc149-based Fusion Proteins
Plasmid pET-28a-HBc149 was constructed as
previously reported [56]. Briefly, the encoding
sequence of HBc149 was inserted into the vector
pET-28a between the restriction endonuclease sites of
Nde I and Hind III. Amino-acids 79-81 were replaced
by GGGGSGGGGT-GS-EF-GGGGSGGGGS in which
GS was coded by a BamH I site and EF was coded by
an EcoR I site. The combination sequences coding for
the gp350 peptides were synthesized (Beijing Ruibio
Biotech Co., Ltd) and inserted into the linearized
vector. The five combinations were: P1-L-P2-L-P3
(3A), where L represents the G4SG4S linker,
P1-L-P3-L-P2 (3B), P2-L-P1-L-P3 (3C), P2-L-P3-L-P1
(3D) and P3-L-P2-L-P1 (3E). The fusion clones were
confirmed by sequencing and the five constructions
were named 149-3A, 149-3B, 149-3C, 149-3D and
149-3E respectively. The wide-type HBc149 vector
was used as a control.

Protein Expression and Purification
Plasmids coding the various constructs were
transformed into BL21 (DE3) competent bacteria.
Positive clones were selected and amplified in liquid
cultures. Then, 5 ml of fresh overnight cultures were
inoculated into 500 ml fresh LB medium in the
presence of 100 mg/L kanamycin at 37°C. Proteins
production was induced by adding IPTG to a final
concentration of 0.5 mM at 30°C for 6-8 h when
OD600=0.8.
The
harvested
bacterial
pellets
were
resuspended in PBS (pH 7.4). After ultrasonication
and high speed centrifugation (25000 x g, 30 min), the
supernatants were collected and precipitated using
30% saturated ammonium sulfate. The precipitated
material was resuspended in PBS and dialyzed
against PBS. The proteins were further purified by gel
filtration using superpose 6 increase 10/300 GL
http://www.thno.org
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columns (GE). The concentration of the target proteins
were determined using BCA assay. The purified
proteins were stored at -80°C prior to use.

SDS-PAGE and Western blotting (WB)
The protein samples were subjected to 12%
SDS-PAGE gels for 1 h at 160 V and the total proteins
were visualized by coomassie brilliant blue staining.
For WB, after SDS-PAGE, proteins were
transferred onto polyvinylidene fluoride membranes
(Millipore). The membranes were blocked with 5%
skim milk in TBST buffer (25 mM Tris, 250 mM NaCl,
0.1% Triton-20, pH 7.4) for 2 h at room temperature.
To detect the HBc149 antigen, mAb 11H10 (gift from
Prof. Xia of Xiamen University) was used (1:2,000
dilution). For detection of gp350 epitopes, an
antiserum prepared in our lab was used (1:1,000
dilution). The membranes were inoculated with
diluted antibodies at 4°C overnight. After three
washes with TBST, membranes were incubated with a
secondary goat anti-mouse antibody (1:10,000,
Promega) conjugated with horseradish peroxidase
(HRP) for 1 h at room temperature. ECL substrate was
used for detection (Advansta).

Transmission Electron Microscopy (TEM)
The recombinant proteins were analyzed by
negative staining electron microscopy. Briefly, protein
samples were diluted to 0.5 mg/ml and applied to
200-mesh carbon-coated copper grids for 5 min.
Excessive solution was removed, grids were washed
twice with double distilled water and then
immediately negatively stained for 30 s with freshly
filtered 2% phosphotungstic acid (pH 6.4). Grids were
examined with a FEI Tecnai T12 TEM (FEI, USA) at an
accelerating voltage of 120 kV and photographed at a
magnification of 25,000 fold.

High Performance Size Exclusion
Chromatography (HPSEC)
All purified proteins were analyzed using a 1120
Compact LC HPLC system (Agilent Technologies;
Santa Clara, CA) and separately with a TSK Gel
PW5000xl 7.8 mm × 300 mm column (TOSOH, Japan);
columns were pre-equilibrated in PBS. The column
flow rate and protein signal detection for the SEC
analysis were 0.5 ml/min and 280 nm.

Indirect Enzyme-Linked Immunosorbent
Assay (ELISA)
Purified gp3501-425-His was coated on 96-well
microplates (Corning) (100 ng/well in PBS) for 2 h at
37°C. The plates were washed once and then blocked
with blocking buffer (PBS pH 7.4, containing 2%
gelatin, 0.5% casein and 0.1% ProClin 300) overnight
at 4°C. Then, 5-fold serial dilutions of sera were added
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to the plates and incubated for 1 h at 37°C. The plates
were washed 5 times and incubated for 30 min at 37°C
with
100
μl
of
horseradish
peroxidase
(HRP)-conjugated goat anti-mouse IgG (Promega)
(1:20,000 dilution). Signals were developed using
EL-TMB kit (Sangon Biotech). Absorbance was
measured at 450 nm using a microplate reader
(Molecular Devices). The cutoff value was set to 0.1
which was determined by the OD450 value of
preimmune sera.

Competitive Enzyme-Linked Immunosorbent
Assay (ELISA)
MAb 72A1 (ATCC cell line ID: HB168)
conjugated with HRP was used in this assay. First,
2-fold dilutions of 72A1-HRP were used to determine
the OD450 for binding to gp3501-425-His coated on the
plates (100 ng/well). A 1.0 value for OD450 was
arbitrarily selected for competition assays and
corresponds to a 1:25,600 dilution. Second, in
competition assay, 2-fold serially diluted sera
(starting from 1:5) were added to the gp3501-425-His
coated plates and incubated for 1 h at 37°C. Then
72A1-HRP (1:25,600 dilution) was added to the plates
after 5 TBST wash and incubated for 30 min at 37°C.
Bound HRP activity was detected using the EL-TMB
kit (Sangon Biotech). The competitive ability of the
sera samples against 72A1 was calculated using the
following equation: Percentage of inhibition
%=[OD(-serum/+72A1)-OD(+serum/+72A1)]/ OD(-serum/+72A1) x
100.

Mouse Immunization Assay
Five female special pathogen free (SPF) female
BALB/C mice (6-8 weeks) per group were immunized
subcutaneously (s.c.). The proteins were formulated
with aluminum hydroxide so that each dose
contained 20 μg purified proteins. One primary
injection dose and two booster doses were given at
two week intervals (week 0, 2, 4). The immunized
mice were bled at weeks 0 (preimmune), 1, 2, 3, 4, 5, 6,
8, 10 and14 for serological tests. All collected sera
were stored at -20°C prior to use.

Infection Blocking Assay
The EBV infection assay was performed as
previously reported [20]. AKATA-EBV-GFP was
produced in CNE2-EBV cells [57]. Representative
mAb 72A1 or 2-fold serial diluted sera (starting from
1:2) were incubated with 100 μl virus stock in 1.5 ml
tubes for 2 h at 37°C. Subsequently, the mixture of
mAb or sera with EBV were added to105 AKATA
negative cells (no latent EBV) at 37°C for 3 h. After
incubation, the cells were pelleted by centrifugation
and washed once using PBS before being cultured in
RPM1640 with 10% FBS in 24-well plates for 48 h. The
http://www.thno.org
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cells were then collected and washed once with PBS.
The EBV infection rate was determined by measuring
the production of GFP expressing cells by flow
cytometry. In this assay, uninfected cells were used as
negative controls and AKATA negative cells
incubated with EBV in the absence of antibodies were
used as positive controls.

Homology Modeling
The crystal structures of gp350ECD123 (PDB no.
2H6O) and HBc149 (PDB no. 1QGT) were used as
templates for homology modeling of the chimeric
monomers. After sequence alignment with the
respective chimeric sequences, the initial 3D models
were generated using the Homology module of
Discovery Studio 2.5 program (Accelrys). HBc149
(PDB no. 1QGT) VLP template was utilized to
generate the complete chimeric VLP models. Stepwise
minimizations were subsequently implemented to the
peptides insertion site of each model to achieve
thermodynamically favored conformations.

Statistics
All statistical analyses were carried out with
GraphPad Prism version 5. p-Values were generated
by one-way ANOVA analysis. p-Values of ≤0.05 were
considered to be statistically significant.

Results
Rational molecular design of fusion proteins
In this study, a C-terminal truncated HBc protein
(aa 1-149, HBc149) was used as a carrier protein to
enhance the immunogenicity of gp350 RBD epitope
peptides. The HBc149 protein was modified and
amino acids 79-81 were substituted with
GGGGSGGGGTGSEFGGGGSGGGGS to provide an
insertion site flanked by flexible G4SG4S linkers (Fig.
1A). This allows for the insertion of foreign epitope
peptides in a site exposed at the surface of VLPs. The
crystal structure of gp350ECD123 has been
determined and the receptor-binding domain was
identified by mutagenesis [22]. Three linear peptides
that form part of the RBD at the surface of gp350 were
selected (Fig. 1B). Sequences of these peptides was
aligned using MEGA 5.05 and Weblogo programs.
The alignments showed high levels of conservation of
all three peptides among 32 EBV gp350 sequences
from Genebank (Fig. 1C). We designed five different
arrangements of three peptides (149-P1/P2/P3,
149-P1/P3/P2, 149-P2/P1/P3, 149-P2/P3/P1 and
149-P3/P2/P1) and the corresponding fusion proteins
were named 149-3A, 149-3B, 149-3C, 149-3D and
149-3E respectively (Fig. 1D). The unmodified HBc149
(wild-type) and soluble gp350ECD123 [27] were used
as controls in subsequent assays.
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Expression and characterization of fusion
proteins
All the fusion proteins were expressed in BL21
(DE3) bacteria. Analysis of HPSEC purified proteins
by SDS-PAGE shows high purity and homogeneity of
each product (Fig. 2A). In addition, mAb 11H10
against HBc149 and antisera against gp350ECD123
recognized the fusion proteins in WB assay (Fig.2B
and 2C).
Particle
profiles
were
analyzed
using
negative-stained TEM and HPSEC (Fig. 3). The results
showed that all the fusion proteins self-assembled
into particles of similar sizes and morphologies. The
inserted peptides in various orders did not have a
detectable effect on the folding and self-assembly of
chimeric HBc149 VLPs.

Immunogenicity of the chimeric VLPs
To assess the immunogenicity of the chimeric
VLP, BALB/c mice (n=5 per group) were inoculated
three times at 2-week intervals with chimeric VLPs
(Fig. 4A). The antigens were formulated with
aluminum adjuvant using 20 μg proteins at each
injection. Serum was collected over 14 weeks and
antibody titer against soluble gp350ECD123 was
determined by ELISA. VLPs 149-3A and 149-3B
elicited higher antibody titer than soluble
gp350ECD123 controls (Fig. 4B). The sera titer
increased to about 5-log for 149-3B and 4.5-log for
149-3A in comparison with 4-log for gp350ECD123 at
1 week after the third injection (week 5). The peak
titers of approximately 6-log for 149-3B and 5-log for
149-3A (4.5-log for gp350ECD123) were measured at 8
weeks, and the sera titer were maintained at 4.5-log
for 149-3A and 149-3B for at least 14 weeks after the
first immunization. The data demonstrated that
selected gp350 peptides presented on 149-3B and
149-3A VLPs can induce higher anti-gp350 antibody
titers than the monomeric gp350ECD123 protein (Fig.
4B).
Surprisingly, the other three fusion proteins,
149-3C, 149-3D and 149-3E did not induce comparable
sera titer, suggesting that the order of gp350 peptides
in HBc149 constructs is critical for immunogenicity of
VLPs. To confirm that all VLPs were equally injected
during immunization, the binding activity of immune
sera to HBc149 was tested (Fig. 4C). There was no
significant difference of antibody titers against
HBc149 for the five fusion proteins and the HBc149
positive control (Fig. 4C). Because VLPs were
generated in bacteria and gp350ECD123 was
produced in insect cells, it could be possible that the
immunogenicity of VLPs was artificially enhanced by
an adjuvant effect due to contamination with high
amounts of lipopolysaccharides (LPS). We therefore
http://www.thno.org
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quantified the levels of endotoxin in the protein
samples that were used for immunization. There was
no difference in endotoxin content between samples
of the various VLPs, and these levels were not
different from levels in the insect cell-produces
gp350ECD sample (Figure S1). These data indicate
that an adjuvant effect of LPS endotoxin contaminants
is not responsible for the difference in
immunogenicity observed in our in vivo experiments.
Overall, our data show that all groups received
similar amounts of purified VLP antigens and that the
difference of anti-gp350 titers observed between
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constructs is due to the presentation of peptides on
VLPs.

Chimeric VLPs (149-3A and 149-3B) induced
potent production of neutralizing antibodies
To determine whether VLP’s elicited antibodies
against a major neutralizing epitope of gp350,
immunized sera were evaluated using a competition
ELISA [27]. The mAb 72A1, is a strong neutralizing
antibody against EBV infection into B cells that binds
to the gp350 RBD [22, 23]. To assess the presence of
serum antibodies against the same neutralizing

Fig. 1. Schematic diagram of the rational design and peptides combination vaccine candidates. (A) Truncated HBV core protein (HBc149) was engineered for
convenient presentation of foreign epitopes. (B) The crystal structure of the gp350 N-terminal (PDB no. 2H6O) is shown as a surface model. The selected three peptides are
colored with yellow (peptide 1, P1), brown (peptide 2, P2) and cyan (peptide 3, P3). The receptor binding domain is circled in purple. (C) Sequence alignment of P1, P2 and P3
peptides using 32 independent sequences from genebank. The sequence logos were generated using weblogo (http://weblogo.berkeley.edu/). Numbers, on the y-axis, represent
the total sequences used in this alignment. (D) Schematic representation of the different constructs. Epitope peptides P1, P2, P3 were inserted into the modified HBc149 vector
in different orders linked with GGGGSGGGGS linker (L).

http://www.thno.org
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epitope, we used a competition ELISA against mAb
72A1. First, we established a binding curve for mAb
72A1-HRP to gp350ECD123 (Fig. 5A). The dilution
fold of 1:25,600 for 72A1-HRP corresponds to a value
of 1.0 OD450 and was selected for competition assays.
In competition assays, serially diluted sera were used
to inhibit binding of 72A1-HRP to gp350ECD123. A
decreased binding of mAb 72A1-HRP indicates the
presence of competing antibodies, presumably to the
same epitope, in immune sera. The results indicated
that sera from mice injected with 149-3A and 149-3B
showed better competition compared to sera from
mice immunized with gp350ECD123 (Fig. 5B). At
5-fold and 10-fold dilution, the sera inhibited more
than 50% binding of 72A1-HRP. As expected, low titer
sera from mice immunized with 149-3C, 3D and 3E
did not efficiently compete with mAb 72A1 binding.
Sera from mice immunized with control HBc149 alone
show a constant background of inhibition, consistent
with previous studies [27, 58]. This competition assay
demonstrates that peptides displayed on HBc-VLPs in
defined orders elicit a potent antibody response
against gp350. Furthermore, competition data showed
that these antibodies detect epitopes which overlap
with the major neutralizing epitope recognized by
mAb 72A1.
To confirm that serum antibodies have a
functional neutralizing activity, an in vitro
neutralization assay was used to evaluate the
efficiency of sera in blocking EBV infection of AKATA
cells. To set up the neutralizing assay, mAb 72A1 was
used as a positive control. In the absence of
antibodies, about 20% of cells were infected by the
EBV-GFP reporter virus. In this assay, the IC50 for
mAb 72A1 was 10.9 μg/ml (Fig. 6A). Serially diluted
sera collected at eight weeks were used. Sera from
mice immunized with 149-3A and 149-3B showed
stronger neutralizing efficiency compared to the sera
raised against soluble gp350ECD123. At 2-fold, 4-fold
and 8-fold dilutions, the sera raised against 149-3A
and 149-3B showed over 50% neutralizing efficiency
against EBV infection. The corresponding ID50 values
are 13.43 and 18.93 for sera from animals immunized
by 149-3A and 149-3B respectively (Table S1).
(Reviewer 3, point 4) Other constructs only show
limited neutralization, close to non-specific activity
and their ID50 values could not be reliably
determined.
To better quantify the efficacy of the different
antigens, sera collected at ten weeks were tested in
this neutralization assay at a 10-fold dilution. Here
again, sera collected from mice immunized with
149-3A and 149-3B blocked EBV infection of AKATA
cells most efficiently (Fig. 6C). Importantly, the
neutralization titers induced by 149-3B and 149-3A
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were significantly higher than that of the other fusion
proteins and the monomeric gp350ECD123. This
monomer is partially glycosylated in insect cells and
can elicit conformation-dependent antibodies. In
contrast, the fusion proteins 149-3A and 149-3B that
were expressed in bacteria and contained linear gp350
peptides that lack glycosylation sites, induced a more
potent neutralization response.

Fig. 2. Analysis of the E.coli-expressed HBc149 fusion proteins by
SDS-PAGE. (A) SDS-PAGE analysis of the purified fusion proteins stained by
coomassie brilliant blue. (B) Western blot analysis of fusion proteins with
anti-HBc149 mAb 11H10. (C) Western blot analysis of fusion proteins with serum
anti-gp350ECD123.

In order to confirm that sera 149-3A and 149-3B
detect gp350 in EBV producing cells, we performed
http://www.thno.org
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IFA staining of AKATA-EBV stimulated cells. In this
assay, the same staining pattern was observed for the
mAb 72A1 and the two neutralizing sera (data not
shown).
In summary, the designed fusion proteins
formed chimeric VLPs with different peptides
combinations. The specific arrangement of three
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gp350 peptides on 149-3A and 149-3B VLPs generated
higher anti-gp350 antibody titers compared to the
subunit gp350ECD123 antigen. The sera collected
from 149-3A and 149-3B VLPs immunized mice
shared overlapped epitopes with mAb72A1 and
neutralized EBV infection of B cells.

Fig. 3. Characterization of self-assembly of the fusion proteins into VLPs. (A) TEM images of suspensions of VLPs (magnification: 25,000x). Scale bars represent 100
nm. (B) Analysis of VLPs by HPSEC. Elution profiles (arbitrary units over time) show that all preparations are highly homogenous. The peak elution time is indicated.
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Fig. 4. Immunogenicity of the purified fusion proteins. (A) Immunization procedure. Immunization (white triangles) and bleeding time points are shown (red drops). (B)
Anti-gp350 titers determination by ELISA. gp350ECD123 was immobilized on 96-well plates and the diluted sera were added for titers determination. The OD450=0.1 was set
as the cut-off value. Significance (*p≤0.05, **p≤0.01, ***p≤0.001) between 149-3A and 149-3B VLPs versus gp350ECD123 is shown. Both constructs 149-3A and 149-3B have the
same level of significance above gp350ECD123. (C) Binding titers of serum antibodies to the vector (HBc149) collected after eight weeks. The error bars indicated the standard
deviation in each group (n=5 mice).

Discussion
Vaccination is proven to be safe and
cost-effective way to protect against pathogen
infections and relevant infectious diseases. To date,
there is no prophylactic vaccine for clinical use against
EBV. Different subunit vaccines have been developed
based on dimeric, tetrameric and polymeric forms of
gp350 which elicited potent neutralizing antibodies

and cytokine responses [15, 26, 27]. Here we
considered peptide-based approach as an attractive
alternative strategy to direct the antibody response
against a neutralizing site of gp350. The N-terminus
fragment gp3501-425 retains the complete binding
activity with the receptor CR2. Therefore, peptides
localized to this region are ideal candidates for a
rational design of EBV vaccines.

http://www.thno.org
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Fig. 5. Blocking the binding of the neutralizing mAb 72A1 to gp350ECD123 in a competition ELISA. (A) Binding of mAb 72A1-HRP to immobilized
gp350ECD123. Serial dilutions of antibody were used to determine the dilution factor corresponding OD450=1.0. (B) Binding of mAb 72A1-HRP to immobilized gp350ECD123
is competed by the indicated immune sera. Serial dilution of sera were applied to gp350ECD123 before the addition of mAb 72A1-HRP in this competition ELISA. Data are shown
as % inhibition of mAb 72A1binding. High inhibition indicates the presence of competing antibodies in the tested sera. Significance (*p≤0.05, **p≤0.01, ***p≤0.001) is indicated for
149-3A and 149-3B VLPs compared to gp350ECD123. Both constructs 149-3A and 149-3B have the same level of significance above gp350ECD123.

In our study, we selected three peptides that
were previously identified by structural modeling,
functional tests, and mutagenesis. The peptide
corresponding to the N-terminus of gp350 (aa 16-29,
IHLTGEDPGFFNVE) binds to CR2, inhibits CR2
binding to immobilized EBV and blocks recombinant
gp350 binding to B cells [43]. The other two peptides
(aa 142-161, HHAEMQNPVYLIPETVPYIK and aa
282-301, YVFYSGNGPKASGGDYCIQS) are involved
in EBV binding to B cells and inhibit mAb 72A1
binding to EBV [44]. In addition, sera collected from
rabbits immunized with these peptides contained
anti-peptide antibody titers between 6,400 and 51,200
and slightly lower antibody titer against EBV
(between 3,200 and 25,600) [44]. The functional
importance of these regions was confirmed by
mutagenesis. Key residues (Glu21, Asp22, Tyr151, Glu155,
Ile160, Trp162, Asp208, Glu210 and Asp296) are located at
the interface between gp350 and CR2 [59]. X-ray
crystallography further identified three discontinuous
peptides at the interface corresponding to
Pro158Tyr159Ile160, Trp162Asp163Asn164 and Asp208Glu210

[22]. All the findings paved the way for rational
design of epitope peptides-based vaccine against EBV.
Often, one peptide epitope may not be sufficient
to induce strong enough immune responses against
viral infection. In this study, three epitope peptides
were simultaneously displayed on the surface of
chimeric VLP with ‘G4SG4S’ as a linker between them.
Our study demonstrated the potential of the chimeric
149-3B and 149-3A combinations to generate
immunogenic VLPs. Interestingly, for 149-3C, 149-3D
and149-3E constructs, the orders of these epitopes
affected the immunogenicity and the neutralizing
activity of sera, but did not appear to influence
assembly of the chimeric VLPs. Figure 7 shows
structural models of the different fusion proteins and
VLPs. Interestingly, the presentation of the peptides
varies considerably between VLPs. Since the peptides
are arranged in the same linear fashion but in
different order (Fig. 1D), the structural variability is
caused by the composition and folding of each
peptide and the flexibility that each combination
allows. The models of 149-3A and 149-3B suggest
http://www.thno.org
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more flexible conformations of the peptides compared
to 149-3C, 3D and 3E. This may allow 149-3A and
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149-3B VLPs to generate stronger neutralizing
antibodies against EBV infection.

Fig. 6. Neutralizing of EBV infection. (A) Neutralizing curve for mAb 72A1 against EBV-GFP infection of AKATA cells. M Ab 72A1 was used to validate the neutralization
assay and its IC50 is indicated. (B) Neutralization of infection by immune sera. Serially diluted sera collected at week 8 were used to block EBV infection of AKATA cells.
Significance (*p≤0.05, **p≤0.01, ***p≤0.001) is indicated for 149-3Aand 149-3B VLPs compared to gp350ECD123. Both constructs 149-3A and 149-3B have the same level of
significance above gp350ECD123. (C) Sera collected at week 10 was diluted 10 fold to block EBV infection into AKATA cells (n=5). Significance (*p≤0.05, **p≤0.01, ***p≤0.001)
between the indicated fusion proteins versus gp350ECD123 is shown. EBV-GFP show the level in the absence of inhibitors. Neg shows the background level in the absence of
infection. 72A1 shows the level of inhibition by mAb 72A1 at 50 μg/ml.
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Fig. 7. Models of fusion proteins and chimeric VLPs corresponding to different constructs. The left, middle and right panels show structural models for monomers
(ribbon), dimers (surface) and chimeric VLPs (surface) of fusion proteins. Homology structural modeling of the recombinant fusion proteins and chimeric VLPs were implemented
using MODELER module of Accelrys Discovery Studio 2.5. All illustrative models were prepared using PyMol. The three peptides are colored with yellow (peptide 1, P1), brown
(peptide 2, P2) and cyan (peptide 3, P3). The peptide insertion site on HBc149 is shown in purple on the wild-type protein and VLP.

Soluble monomeric gp350 is a relatively poor
antigen, which immunogenicity is increased by about
20-fold through tetramerization [26, 60]. We also
previously showed increased immunogenicity

through dimerization of gp350ECD123 [27]. Several
other approaches with full-length or truncated gp350
showed superior immunogenicity and ability to
induce neutralizing antibodies [60]. Peptide antigens
http://www.thno.org
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do not elicit antibodies against conformationdependent epitopes, thus linear peptides often have
reduced immunogenicity compared to proteins.
Despite this intrinsic shortcoming, our selection of
three peptides from a functional site on gp350
induced a better neutralization response than
monomeric gp350ECD123. Nevertheless, our data
reveal some limitation of the use of peptides, notably
the effect of the positioning of the peptides on
HBc-149 VLPs. Although peptide antigens offer the
advantage of combining several targeted epitopes, the
presentation of peptide antigen in VLPs need further
improvement to reach the immunogenicity level of
protein multimers.
Many factors can affect the success of
peptide-based vaccines, our data highlight the
importance of the order of epitopes when designing
vaccines based on multiple epitopes. In addition to
peptide display, VLPs, may affect epitope
immunogenicity due to their own physical properties
(e.g. posttranslational modifications, aggregation,
solubility, intrinsic immunogenicity). Our data show
that in the presence of aluminum hydroxide adjuvant,
VLPs with peptide antigens performed better than the
soluble protein antigen in eliciting neutralizing
antibodies. Different adjuvants could help to further
enhance the immunogenicity of chimeric VLPs [49].
In previous studies, gp350 was used as the major
immunogen for vaccine development, although it is
only effective in preventing infection of B cells.
However, EBV encodes at least thirteen envelope
glycoproteins that could be considered in vaccine
design [61, 62]. In particular, glycoproteins involved
in the viral fusion apparatus (gL/gH, gp42 and gB)
have become very promising targets for the
development of prophylactic vaccines. Immunization
with nanoparticles or multimeric forms of these
glyproteins elicited robust neutralizing antibodies
able to protect B cells as well as epithelial cells [13-15,
60]. Indeed, potent neutralizing epitopes were
localized on gH/gL, gB and gp42 [63, 64]. Antibodies
raised against three epitope peptides derived from gH
could inhibit the interaction between EBV and cord
blood lymphocytes [63]. Additional peptide epitopes
identified in silico and in functional assays also
warrant further functional investigation [64-67].
Several CTL epitopes were identified in gp350 and,
interestingly, among the peptides that bound
HLA-A2, the LIPETVPYI peptide is contained within
peptide P2 used in the present study [65]. However
this peptide failed to efficiently stimulate CTL
effectors from IM donors ex vivo [65]. In that study, a
more distant gp350 peptide (VLQWASLAV, aa
863-871) was able to induce a functional CTL response
ex vivo and in HLA-A2 transgenic mice, which became
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protected against a gp350-expressing recombinant
vaccinia virus [65]. Linear CD4 T-cell epitopes were
also identified in gp350 (incl. aa 65-75,
FGQLTPHTKAV and aa 163-183, DNCNSTNITAVVR
AQGLDVTL) [66]. Therefore, future designs of
peptide vaccines will successfully include various
epitopes from different antigens and integrate B and T
cell epitopes into one antigenic formulation [9, 60].
VLPs based on HBc149 provide an appropriate
platform to engineer complex peptide-based epitopes.
Our study opens the possibility to develop
pluripotent vaccines by combining HBc149-derived
VLPs engineered to express B and T cell peptide
epitopes from different EBV glycoproteins.
This work provides encouraging results towards
the design of novel EBV vaccine candidates on the
basis of HBc protein mosaic VLPs that display epitope
peptides derived from gp350. More generally, our
data provide proof of principle for EBV vaccine
design combining multiple antigenic epitopes on
HBc149 VLPs. A multi-peptide strategy that includes
epitopes from the fusion machinery (gL, gH, gp42 and
gB) in addition to gp350 will further enhance the
efficacy of VLPs as vaccines against EBV.

Conclusion
Three epitopes among different strains derived
from the receptor binding domain of EBV envelope
protein gp350 were combined to be displayed on the
surface of chimeric HBc149 VLPs. These well-formed
spherical bionanoparticles were characterized by a
combination of physico-chemical methods. Among
these five VLPs, 149-3A and 149-3B showed higher
immunogenicity compared to purified gp350ECD123.
More importantly, these two particles induced
stronger neutralizing antibodies in mice to block EBV
infection in a cell model. Therefore, different
combinations of epitopes could affect the overall
immune response. Consequently, HBc149-based
chimeric VLPs provided an effective platform for the
development of novel peptide-based candidate
vaccines against EBV.
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